Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05367180 | The Impact of a Prevention Program on Sun Risks in Primary School in Tropical French Region(PRESOLRE) | completed | N/A | 1,452 | Centre Hospitalier Universitaire de la RéunionOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT02126579 | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists(MEL60) | completed | Phase 1 / Phase 2 | 50 | Craig L Slingluff, JrOTHER | 1 | Feb 28, 2024 |
| clinicaltrials |
| NCT02694965 | Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma | completed | — | 122 | Duke UniversityOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT03617328 | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma(Mel-65) | completed | Phase 1 / Phase 2 | 33 | Craig L Slingluff, JrOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03798977 | Preclinical Validation of New Anti-melanoma Compounds(ERMELATHER) | completed | — | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03052127 | Study in Subjects With Small Primary Choroidal Melanoma | completed | Phase 1 / Phase 2 | 57 | Aura BiosciencesINDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT02875652 | Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)(ctDNA MU) | completed | N/A | 800 | Institut CurieOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01785316 | The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases(SCANDIUM) | completed | Phase 3 | 93 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT03073304 | A Randomized Controlled Study Comparing Priming Solution Containing Crystalloid or Packed Red Blood Cells in Patients Treated With Isolated Limb Perfusion.(ILP-Prime) | completed | N/A | 18 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT03879395 | Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study(SurgMelMet) | completed | — | 15 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT00866840 | Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05432622 | A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy | completed | — | 95 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03850691 | Radiation and Combination Immunotherapy for Melanoma | completed | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03535077 | Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging) | completed | — | 186 | Orlucent, IncINDUSTRY | 1 | Jan 10, 2024 | clinicaltrials |
| NCT03765229 | An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma | completed | Phase 2 | 11 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT00046189 | Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum | completed | — | 301 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06189261 | Holistic Needs Assessments in Patients With Melanoma | completed | — | 30 | University of SurreyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT03123783 | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | completed | Phase 1 / Phase 2 | 140 | Apexigen America, Inc.INDUSTRY | 2 | Dec 26, 2023 | clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT02482168 | Study of the CD40 Agonistic Monoclonal Antibody APX005M | completed | Phase 1 | 43 | Apexigen America, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT01531608 | Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma(Mel54) | completed | — | 20 | University of VirginiaOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03980314 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | completed | Phase 1 | 261 | Bristol-Myers SquibbINDUSTRY | 14 | Dec 15, 2023 | clinicaltrials |
| NCT03267381 | Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy | completed | — | 37 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT02101008 | Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy | completed | Phase 2 | 12 | University of UtahOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT02697630 | Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye(PEMDAC) | completed | Phase 2 | 29 | Vastra Gotaland RegionOTHER_GOV | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02223819 | Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy | completed | Phase 2 | 34 | Columbia UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04834167 | OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women | completed | N/A | 32 | Universiti Tunku Abdul RahmanOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06152367 | Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients | completed | Phase 1 / Phase 2 | 90 | University of ChileOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT02799901 | Nivolumab Plus Radiotherapy in Advanced Melanoma(NIRVANA) | completed | Phase 2 | 72 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT03089606 | Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker | completed | Phase 2 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02729298 | First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors | completed | Phase 1 | 177 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04406454 | The Application of Non-invasive and Cellular Level Resolution Fullfield Optical Coherence Tomography: Establishment and Analysis of Subcutaneous Cellular Level Image Database of Anatomical Locations in Healthy Volunteers and Evaluation of Usability | completed | — | 60 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04904120 | Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy(TIMAR1) | completed | Phase 1 | 7 | Perspective TherapeuticsINDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02407171 | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | completed | Phase 1 / Phase 2 | 61 | Yale UniversityOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT00617799 | Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma | completed | — | 15 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04534309 | Behavioral Weight Loss Program for Cancer Survivors in Maryland(ASPIRE) | completed | N/A | 340 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00588198 | Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma | completed | — | 754 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04059224 | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma(TraMel-WT) | completed | Phase 2 | 45 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02403778 | Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | completed | Phase 2 | 10 | University of Colorado, DenverOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT02310451 | Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes(EXOSOMES) | completed | N/A | 15 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT02768766 | Intermittent Selumetinib for Uveal Melanoma | completed | Phase 1 | 42 | Shaheer A. KhanOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT02515227 | Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab(Mel64) | completed | Phase 1 / Phase 2 | 22 | Craig L Slingluff, JrOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT01152788 | Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma | completed | Phase 2 | 64 | NCIC Clinical Trials GroupNETWORK | 2 | Aug 22, 2023 | clinicaltrials |
| NCT02273219 | Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | completed | Phase 1 | 30 | Columbia UniversityOTHER | 1 | Aug 15, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 29, 2024source: clinicaltrials